Sulfur Hexafluoride
Early-Onset Autosomal Dominant Alzheimer Disease
Explore 22 assets in Early-Onset Autosomal Dominant Alzheimer Disease →Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Columbia University
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06600880CT.gov Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Early-Onset Autosomal Dominant Alzheimer Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sulfur Hexafluoride (this asset) | Columbia University | P1 | CC · 41 |
| Donanemab | Banner Health | P2/3 | B |
| RG6289 | Banner Health | P2/3 | B |
| Gonadorelin | Nelly Pitteloud | P2/3 | CCC |
| Gnrh | Nelly Pitteloud | P2/3 | CCC |
| Physiologic Sodium Chloride Solution | Nelly Pitteloud | P2/3 | CCC |
| Flavone, 3,3',4',5,7-Pentahydroxy- | Washington University School of Medicine | P2 | CCC |
| ad-35 | Zhejiang Hisun Pharmaceutical Co. Ltd. | P2 | CCC |
| Bms-986446 | Bristol-Myers Squibb | P2 | CCC |
+18 more in the Early-Onset Autosomal Dominant Alzheimer Disease cohort
Other indications for Sulfur Hexafluoride
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BB · 67 |
| Stroke Disorder | — | P2 | B · 62 |
| Carotid Stenosis | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sulfur Hexafluoride in Early-Onset Autosomal Dominant Alzheimer Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sulfur-hexafluoride-early-onset-autosomal-dominant-alzheimer-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →